Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 3

Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)

NCT00014989 · View on ClinicalTrials.gov ↗

Study Summary

As many more premature infants survive, the numbers of these infants with health problems increases. The rate of cerebral palsy (CP) in extremely premature infants is approximately 20%. Magnesium sulfate, the most commonly used drug in the US to stop premature labor, may prevent CP. This trial tests whether magnesium sulfate given to a woman in labor with a premature fetus (24 to 31 weeks out of 40) will reduce the rate of death or moderate to severe CP in the children at 2 years. The children receive ultrasounds of their brains as infants and attend three follow-up visits over two years to assess their health and development.

Interventions

  • DRUG magnesium sulfate

Study Locations (17)

Ohio

  • The University Hospital, University of Cincinnati — Cincinnati
  • Case Western University — Cleveland
  • Dept of OB/GYN, Ohio State University — Columbus

Texas

  • Dept of OB/GYN, Southwestern Medical Center, University of Texas — Dallas
  • University of Texas Medical Branch - Galveston — Galveston
  • University of Texas - Houston — Houston

North Carolina

  • University of North Carolina — Chapel Hill
  • Forsyth Memorial Hospital, Wake Forest University School of Medicine — Winston-Salem

Pennsylvania

  • MCP Hahnemann University — Philadelphia
  • Dept of OB/GYN Magee Womens Hospital — Pittsburgh

Alabama

  • University of Alabama — Birmingham

Florida

  • Dept of OB/GYN, University of Miami — Miami

Illinois

  • Northwestern University — Chicago

Michigan

  • Dept of OB/GYN, Hutzel Hospital — Detroit

Trial Details

FieldValue
Enrollment Target 2,136 participants
Start Date 1997-12
Est. Completion 2007-06
Phase Phase 3

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00014989

The ClinicalTrials.gov registry entry for NCT00014989 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 2,136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The George Washington University Biostatistics Center, which has 7 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 5 conditions, with Cerebral Palsy appearing as the primary indexed condition, and to 1 intervention — of which magnesium sulfate is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00014989 reports 17 study locations spanning 11 distinct geographic areas — top geographies include Ohio, Texas, North Carolina. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00014989 about?

NCT00014989 is a clinical study titled "Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)". As many more premature infants survive, the numbers of these infants with health problems increases. The rate of cerebral palsy (CP) in extremely premature infants is approximately 20%. Magnesium sulfate, the most commonly used drug in the US to stop premature labor, may prevent CP. This trial tests...

What is the current status of trial NCT00014989?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,136 participants. The study started on 1997-12. Estimated completion is 2007-06.

What conditions does trial NCT00014989 study?

This clinical trial studies the following conditions: Cerebral Palsy, Intraventricular Hemorrhage, Pulmonary Edema, Periventricular Leukomalacia, Abruptio Placentae. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00014989?

The interventions under investigation include: magnesium sulfate (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00014989?

This trial is sponsored by The George Washington University Biostatistics Center, which has 7 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00014989 being conducted?

This trial has 17 study locations across Alabama, Florida, Illinois, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial